Clinical Care Options Oncology - Colorectal CancerThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

Pages: 1 2

96 records returned

Selected Currently Enrolling Phase II/III Clinical Trials in CRCEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Download slides on currently enrolling phase II/III clinical trials in colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - November 13, 2009 Category: Cancer & Oncology Source Type: journals

Microsatellite Instability Predicts Improved Response to Adjuvant Therapy With Irinotecan, Fluorouracil, and Leucovorin in Stage III Colon CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Download slides exploring the relationship between microsatellite instability and response to irinotecan, fluorouracil, and leucovorin in the adjuvant setting in stage III colon cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - November 12, 2009 Category: Cancer & Oncology Source Type: journals

Cases Cubed: 3 Cases, 3 Expert Opinions in Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Discussion, Axel Grothey, MD; Cathy Eng, MD; Richard M. Goldberg, MD; and Nancy Roach explore current thinking regarding the clinical management of patients with colorectal cancer in 3 case scenarios. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - November 4, 2009 Category: Cancer & Oncology Source Type: journals

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Download slides summarizing the CAIRO2 study of chemotherapy, bevacizumab, and cetuximab in patients with metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - October 15, 2009 Category: Cancer & Oncology Source Type: journals

Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - Download slides on several of the most important data in CRC presented at the 2009 annual Clinical Oncology meeting in Orlando. Topics include new data from biomarker studies, updates in early-stage disease, new findings in locally advanced CRC, and data from studies evaluating ways to minimize treatment-related toxicity. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 23, 2009 Category: Cancer & Oncology Source Type: journals

IV CaMg, Picoplatin Both Effective Strategies in Reducing Treatment-Related Sensory Neuropathy in Patients With Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - In a randomized, placebo-controlled phase III trial, IV CaMg protected against oxaliplatin-related chronic sensory neuropathy vs placebo in the adjuvant setting; in a separate randomized study, picoplatin was shown to be an effective alternative to oxaliplatin with less sensory neuropathy when used in combination with 5-fluorouracil and leucovorin for the first-line treatment of metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 4, 2009 Category: Cancer & Oncology Source Type: journals

Recurrence Score Defined Prospectively Using Gene Expression Assay Predicts Recurrence Risk in Stage II Colon CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - The study is the first to illustrate that a gene expression assay can be used to independently predict colon cancer recurrence risk, according to investigators. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 3, 2009 Category: Cancer & Oncology Source Type: journals

Relationship Between KRAS Status and Treatment Benefit Shown in Metastatic Colorectal Cancer Patients Receiving Panitumumab and FOLFIRIEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Results from 2 phase II studies show that the combination of panitumumab and FOLFIRI is more effective in metastatic colorectal cancer patients with wild-type vs mutated KRAS. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 2, 2009 Category: Cancer & Oncology Source Type: journals

Preliminary Data Support Utility of 18q Loss of Heterozygosity as a Prognostic Marker in Early-Stage Colon CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Loss of heterozygosity at 18q was associated with significantly lower DFS and OS among patients with stage II colon cancer enrolled in the randomized CALGB 9581 trial. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 2, 2009 Category: Cancer & Oncology Source Type: journals

Benefit From Addition of Cetuximab to Chemotherapy Associated With Rash; Survival Improved in NSCLC Regardless of KRAS Status or EGFR Copy NumberEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - The benefit from adding cetuximab to standard first-line chemotherapy is associated with rash and improves survival in NSCLC, regardless of KRAS mutation status or EGFR positivity. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 2, 2009 Category: Cancer & Oncology Source Type: journals

ACCENT: 2-Year DFS Validated as a Primary Endpoint for OS With 5-FU–Containing Regimens in Patients With Stage III Colon CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Analysis of data from 6 recent adjuvant colon cancer trials added to the ACCENT database showed a strong concordance between both 2-year and 3-year DFS. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 2, 2009 Category: Cancer & Oncology Source Type: journals

Neoadjuvant Cisplatin Effective in Small Study of BRCA1-Positive Breast Cancer PatientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Cisplatin neoadjuvant therapy produces high pathological response rates in BRCA1-positive breast cancer patients. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 1, 2009 Category: Cancer & Oncology Source Type: journals

No Effect on Tumor Response With Weekly Oxaliplatin Added to Standard Preoperative 5-FU/RT in Locally Advanced Rectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Addition of oxaliplatin to standard preoperative chemoradiotherapy does not significantly improve tumor response (size, stage, or nodal involvement) in locally advanced rectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - May 31, 2009 Category: Cancer & Oncology Source Type: journals

Addition of Oxaliplatin to Standard Preoperative Chemoradiotherapy Not Beneficial in Rectal Cancer: Results of the ACCORD 12/0405 TrialEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - The addition of oxaliplatin to preoperative chemoradiotherapy had no significant effect on tumor response or outcomes in patients with locally advanced, stage T3-4 rectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - May 31, 2009 Category: Cancer & Oncology Source Type: journals

70-Gene Expression Profile Predicts Chemotherapy Benefit in Patients With Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - The addition of adjuvant chemotherapy to hormonal therapy benefits breast cancer patients classified as high risk. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - May 31, 2009 Category: Cancer & Oncology Source Type: journals

Microsatellite Instability and Other Molecular Alterations of Colon Cancer Offer Stage-Specific Prognostic ValueEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Analyses of a major European study revealed that microsatellite instability was one strong prognostic factor for RFS and OS in stage II colon cancer. Results of further analysis showing the stage-specific prognostic value of various markers led investigators to consider that disease “stages” may actually represent distinct diseases, rather than an evolution of a single disease. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - May 29, 2009 Category: Cancer & Oncology Source Type: journals

Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy Does Not Prolong DFS in Stage II/III Colon CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - The addition of bevacizumab to oxaliplatin-based chemotherapy does not significantly prolong DFS in patients with stage II/III colon cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - May 29, 2009 Category: Cancer & Oncology Source Type: journals

Biomarker Studies Clarify Role of KRAS and Other Molecular Predictors of EGFR-Targeted Therapy Benefit in Advanced Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Capsule Summary - Combined wild-type KRAS status and high EREG expression was identified as predictive of cetuximab benefit; in a separate study, both KRAS and BRAF mutation were shown to be strong negative predictors of cetuximab or panitumumab efficacy. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - May 29, 2009 Category: Cancer & Oncology Source Type: journals

Expert Analysis: Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Edward Chu, MD; Richard Goldberg, MD; and Alan Venook, MD, discuss the clinical implications of the most recent data in colorectal cancer, including the prognostic and predicative value of molecular biomarkers, the role of VEGF inhibitors, the correlation of disease-free survival and overall survival, and the impact of older age on the efficacy of newer adjuvant therapies in stage II and III disease. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - March 11, 2009 Category: Cancer & Oncology Source Type: journals

ASCO 2009: Colorectal Cancer Expert RecapEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Expert Recap - Alan P. Venook, MD, explores the most compelling data in colorectal cancer presented at the 2009 Clinical Oncology meeting. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - January 7, 2009 Category: Cancer & Oncology Source Type: journals

Adding Cetuximab to Capecitabine, Oxaliplatin, and Bevacizumab Shortens PFS in Advanced Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In patients with advanced colorectal cancer and KRAS mutation, adding cetuximab to capecitabine, oxaliplatin, and bevacizumab is associated with a significant shortening of PFS (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - November 13, 2008 Category: Cancer & Oncology Source Type: journals

Phase III CONcePT Trial: In mCRC, Intermittent Oxaliplatin Extends Time to Treatment FailureEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Final results from the phase III CONcePT trial demonstrate that intermittent oxaliplatin compared with continuous treatment increases time to treatment failure in patients with mCRC. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - October 30, 2008 Category: Cancer & Oncology Source Type: journals

IV Calcium and Magnesium Protect Against Oxaliplatin-Induced Neurotoxicity in Colon Cancer Patients Receiving Adjuvant FOLFOXEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Despite early termination based on negative results from a different study, a randomized, controlled trial demonstrated that IV calcium and magnesium reduced neurotoxicity in patients with stage II/III colon cancer receiving adjuvant FOLFOX (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - October 24, 2008 Category: Cancer & Oncology Source Type: journals

Mismatch Repair Marker Predicts Benefit of 5-FU-Based Chemotherapy in Patients With Stage II/III Colon CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In stage II/III chemotherapy-naive colon cancer patients, deficient mismatch repair predicts lack of benefit from 5-FU-based chemotherapy (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - September 23, 2008 Category: Cancer & Oncology Source Type: journals

In Large Phase III Trial, Bevacizumab Plus mFOLFOX6 Seen as Well Tolerated in Adjuvant Treatment of Advanced Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In initial safety analysis from NSABP C-08, bevacizumab added to mFOLFOX6 appears well tolerated in the adjuvant setting for patients with stage II or III advanced colorectal cancer with no compromise in FOLFOX6 dose intensity (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - September 19, 2008 Category: Cancer & Oncology Source Type: journals

NSABP C-07 Update: Trend Points to Improved 5-Year Survival With Adjuvant Oxaliplatin Added to 5-FU/LV in Colon CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Latest data from large phase III trial in patients with stage II/III colon cancer suggest improved OS at 5 years-and confirm superior PFS-for oxaliplatin added to 5-FU/LV in adjuvant therapy (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - August 27, 2008 Category: Cancer & Oncology Source Type: journals

Unnecessary Surgery Prevented for Patients With Colorectal Liver Metastases When FDG-PET Added to CT Scan StagingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Addition of FDG-PET to CT scan results in decreased number of unnecessary laparotomies in patients with colorectal liver metastases (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - August 13, 2008 Category: Cancer & Oncology Source Type: journals

Gastrointestinal Cancer: Expert RecapEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Expert Recap - John L. Marshall, MD, discusses highlights from several of the key studies presented at the 2008 Annual Meeting of the American Society of Clinical Oncology, including advances in the role of biomarkers in gastrointestinal cancer treatment efficacy. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - July 31, 2008 Category: Cancer & Oncology Source Type: journals

Benefit of Cetuximab Plus Irinotecan in Previously Irinotecan-Refractory mCRC Confined to Patients Without KRAS MutationsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cetuximab, in standard or escalating doses, combined with irinotecan induces responses in mCRC patients in whom the chemotherapeutic agent previously failed, but only in those with wild-type KRAS (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - July 26, 2008 Category: Cancer & Oncology Source Type: journals

Gastrointestinal CancersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Axel Grothey, MD, John L. Marshall, MD, and Richard M. Goldberg, MD, examine new data on biomarkers and response to biologic and chemotherapeutic agents in colorectal cancer, combination adjuvant treatment regimens in colorectal cancer, chemotherapy in advanced pancreatic cancer, and other topics—and discuss implications for clinical practice. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - July 25, 2008 Category: Cancer & Oncology Source Type: journals

CCO Independent Conference Coverage of the 2008 American Association for Cancer Research Annual MeetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Learning Module - Roy S. Herbst, MD, PhD, and Andrew X. Zhu, MD, PhD, discuss recent clinical trial data and novel targets presented at the 2008 American Assciation for Cancer Research meeting. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 26, 2008 Category: Cancer & Oncology Source Type: journals

Cetuximab Benefit With FOLFOX in mCRC Limited to Wild-Type KRAS TumorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Adding cetuximab to FOLFOX benefits metastatic colorectal cancer patients with wild-type KRAS tumors, but not those with mutant KRAS (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 25, 2008 Category: Cancer & Oncology Source Type: journals

Cetuximab Addition to FOLFIRI Only Benefits Colorectal Cancer Patients With Wild-Type KRASEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Retrospective efficacy analysis of CRYSTAL trial reveals that addition of cetuximab to FOLFIRI appears to only benefit metastatic colorectal cancer patients with wild-type KRAS (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 14, 2008 Category: Cancer & Oncology Source Type: journals

EGFR-Targeted Antibodies: Clinical Applications, Treatment Challenges, and Ongoing Scientific ResearchEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CCO Slideset - David Cunningham, MD, FRCP discusses the rationale for targeting the EGFR with monoclonal antibodies and gives an update on their use in gastrointestinal cancers as monotherapy and in combination with chemotherapies. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - June 12, 2008 Category: Cancer & Oncology Source Type: journals

Master Class in Management of Liver Metastases From Colorectal Cancer: Case-Based LearningEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Steven R. Alberts, MD, reviews recent data on current and novel therapeutic approaches for managing liver metastases in patients with colorectal cancer and examines how this knowledge is applied in practice in 3 patient cases. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - April 24, 2008 Category: Cancer & Oncology Source Type: journals

Conference Report From the 2008 Gastrointestinal Cancers Symposium: Colorectal CancersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Alan P. Venook, MD, and Richard M. Goldberg, MD, discuss results presented at the 2008 Gastrointestinal Cancers Symposium regarding current therapy for colorectal cancers. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - April 12, 2008 Category: Cancer & Oncology Source Type: journals

Exploring Biomarkers and Surrogates in Optimizing Patient OutcomesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Eric Van Cutsem, MD, PhD, discusses the emerging use of biomarkers in the clinical management of patients with metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - April 11, 2008 Category: Cancer & Oncology Source Type: journals

Controversies in Care: Using Clinical Data to Guide Treatment SelectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cathy Eng, MD, reviews recent data regarding the use of clinical data to optimize treatment of colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - March 19, 2008 Category: Cancer & Oncology Source Type: journals

Potentially Curable Metastatic Disease in Colorectal Cancer: Neoadjuvant Approach to Liver-Limited DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Edward Chu, MD, reviews neoadjuvant strategies to improve outcomes in patients with liver-limited metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - March 14, 2008 Category: Cancer & Oncology Source Type: journals

Update on the Science of Current Therapy for Metastatic Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
J. Randolph Hecht, MD, reviews current therapeutic options for metastatic colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - March 13, 2008 Category: Cancer & Oncology Source Type: journals

Update on the Use of Oral Therapies in Colon and Rectal CancersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
David H. Ilson, MD, PhD, describes recent data on treatment approaches using oral agents in the management of colon and rectal cancers. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - November 13, 2007 Category: Cancer & Oncology Source Type: journals

Case: Management of a 65-Year-Old Male With Metastatic Colorectal Cancer and Gilbert's SyndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Alan P. Venook, MD reviews options for cytotoxic and targeted agents as first-line treatment of a patient with metastatic colorectal cancer and Gilberts syndrome. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - November 7, 2007 Category: Cancer & Oncology Source Type: journals

Advanced Colorectal Cancer and Novel TherapiesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Daniel G. Haller, MD, reviews the current treatment of advanced colorectal cancer and discusses emerging therapies. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - October 30, 2007 Category: Cancer & Oncology Source Type: journals

Colorectal Cancer Detection and DiagnosisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Heinz-Josef Lenz, MD, reviews modalities for the detection and imaging of colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - October 3, 2007 Category: Cancer & Oncology Source Type: journals

Adjuvant Treatment for Colon CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Richard M. Goldberg, MD, reviews the current use of adjuvant chemotherapy for patients with colon cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - September 21, 2007 Category: Cancer & Oncology Source Type: journals

Colorectal Cancer PreventionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Axel Grothey, MD, reviews strategies to decrease the risk of colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - September 14, 2007 Category: Cancer & Oncology Source Type: journals

Adjuvant Treatment for Rectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Joel E. Tepper, MD, reviews the current use of adjuvant chemotherapy for patients with rectal cancer (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - September 11, 2007 Category: Cancer & Oncology Source Type: journals

Colorectal Cancer: Demographics and ScreeningEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dennis J. Ahnen, MD, reviews current and emerging screening techniques for colorectal cancer. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - September 7, 2007 Category: Cancer & Oncology Source Type: journals

Expert Analysis: Gastrointestinal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Axel Grothey, MD, John L. Marshall, MD, and Alan P. Venook, MD, review data from the meeting in Chicago. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - August 7, 2007 Category: Cancer & Oncology Source Type: journals

EGFR, HER2, and K-RAS Biomarkers Predict Response to Cetuximab in Colorectal CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Results of a retrospective analysis of biomarkers in metastatic colorectal cancer suggested that a combination of EGFR copy number and K-ras mutational status may improve prediction of response to cetuximab therapy. (Source: Clinical Care Options Oncology - Colorectal Cancer)
Source: Clinical Care Options Oncology - Colorectal Cancer - July 24, 2007 Category: Cancer & Oncology Source Type: journals